My laboratory is focused on developing novel treatment approaches for certain leukemias and lymphomas utilizing the patient’s own immune system. Specifically this work involves the genetic manipulation of patients’ immune cells to recognize and kill their own cancer cells. This is a promising form of gene therapy.
In light of encouraging results in mouse studies, we are now testing this approach at Memorial Sloan Kettering in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia who are no longer responsive to chemotherapy. These highly innovative studies will hopefully result in a novel and successful treatment option for patients with certain forms of hematologic cancers.
Renier J. Brentjens, MD, PhD
Director, Cellular Therapeutics; Member in Human Oncology and Pathogenesis Program (HOPP)
Research FocusPhysician-scientist Renier Brentjens develops novel immunotherapies for leukemias and lymphomas.
EducationMD, PhD, The State University of New York at Buffalo, School of Medicine and Biomedical Sciences
- STRAP Supplemental Award, National Cancer Institute (2010-2013)
- William Lawrence Blanche Hughes Foundation Grant (2011-2016)
- CLL Global Research Foundation Grant (2009-2014) R01 Award, National Institutes of Health (2009-2014)
- Experimental Therapeutics Center Program Project Grant, National Institutes of Health (2009-2014)
- Geoffrey Beene Cancer Research Center Fund Award (2007-2009)
- Experimental Therapeutics Center Program Project Grant, National Institutes of HEalth (2005-2010)
- Clinical Investigator Award, Damon Runyon Foundation (2006-2011)